Drug General Information |
Drug ID |
D0J6ME
|
Former ID |
DNC008471
|
Drug Name |
2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C13H11N3S
|
Canonical SMILES |
CCC1=NC2=C(C(=N1)C3=CC=CC=N3)SC=C2
|
InChI |
1S/C13H11N3S/c1-2-11-15-10-6-8-17-13(10)12(16-11)9-5-3-4-7-14-9/h3-8H,2H2,1H3
|
InChIKey |
RJLBQJZGTPMDPY-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Sphingolipid signaling pathway
|
Neuroactive ligand-receptor interaction
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
Calcium signaling pathway
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation
|
G alpha (s) signalling events
|
Surfactant metabolism
|
WikiPathways
|
Nucleotide GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
Monoamine Transport
|
NGF signalling via TRKA from the plasma membrane
|
GPCR downstream signaling
|
GPCRs, Other
|
References |
REF 1 | Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. Epub 2008 Mar 30.Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. |